4g/L) levels of serum IgG4 and no histological evidence of IAC, this percentage was 22%. Our actual

findings together with our recent observation of clonal expansions of IgG4 switched B-cells in IgG4-RD provide support for the idea that chronic exposure to occupational antigens may play a key role in the initiation and/or maintenance of IgG4-RD. Our findings may yield more insight in the Selleck ABT-263 aetiology of this poorly understood disease and provide directions for the optimization of its therapy. Disclosures: Emma L. Culver – Grant/Research Support: Wellcome Trust Research Fellowship, Merck-funded Oxford AcademicFellowship Roger W. Chapman – Advisory Committees or Review Panels: falk, takeda; Speaking and Teaching: roche; Stock Shareholder: gilead Ulrich Beuers – Consulting: Intercept; Grant/Research Support: Zambon; Speaking and Teaching: Falk Foundation, Gilead, Roche, Scheringh, Zambon The following people have nothing to disclose: Lucas Maillette

de Buy Wenniger, Eleanor Barnes Objective: Elevated serum concentration of IgG4 is reported in up to 10% of patients with primary sclerosing cholangitis (PSC), a heterogeneous Belinostat mw disorder of unknown aetiology. High IgG4 is associated with more severe disease, yet with some extent of corticosteroid responsiveness. We hypothesized that these patients represent a distinct subgroup of PSC and aimed to explore clinical and genetic aspects of high IgG4 in a large Norwegian cohort. Methods: We included 263 PSC patients with stored DNA and serum available. Patients with high IgG4 were defined by cut-off levels of a) 1.35g/l (as applied in previous studies on IgG4 related disease) and b) 2.01 g/l (upper reference limit). Genotypes of the strongest genetic risk factors in PSC, HLA-B and HLA-DRB1, were

available from the patients 上海皓元 and 368 healthy controls. Results: N=47 (18%) and n=23 (9%) PSC patients had high IgG4 when applying cut-off levels of IgG4>1.35 and IgG4>2.01 respectively. The HLA-B*08 allele, consistently observed as the top genetic risk factor in PSC, was less prevalent in patients with high than low IgG4 (29% vs 42%, P=0.02, for cut-off IgG4>1.35 and 26% vs 41%, P=0.05, for cut-off IgG4>2.01). In contrast, the PSC-associated alleles HLA-B*07 and DRB1*15 were more prevalent in PSC with high than low IgG4, but only when applying the IgG4>2.01 cut-off (HLA-B*07: 24% vs 13%, P=0.04 and DRB1*15: 26% vs 14%, P=0.04, for high vs low IgG4, respectively). When comparing patients with healthy controls, HLADRB1*15 was significantly associated only with PSC with IgG4>2.01 (26% vs 15%, P=0.05), while there was no association with HLA-DRB1*15 in this PSC population as a whole (P=0.90). Clinically, IgG4>1.35 was associated with shorter liver transplantation free survival (P=0.05) and shorter survival to the end-point of death only (P=0.007), while there were no differences between high and low IgG4 regarding gender (87% vs 75% male, P=0.09) or inflammatory bowel disease (IBD) (82% vs 82%).